Why Cerezyme?

With 17 years of history of effectiveness in controlling and reversing many of the effects of Type 1 Gaucher disease, Cerezyme has been prescribed for more than 5,600 patients in more than 90 countries around the world.

Cerezyme:

  • Has been demonstrated to reverse many of the blood and organ-related symptoms of Type 1 Gaucher disease such as anemia (low red blood cell count), thrombocytopenia (low blood platelet count), bone disease, and hepatomegaly or splenomegaly (enlarged liver or spleen)
  • Is supported by 17 years of clinical data and experience
  • Is backed by Genzyme’s comprehensive educational programs, insurance reimbursement support, and clinical research

Cerezyme has shown the positive impact that treatment can have on many manifestations of the disease. Data generated by the Gaucher Registry, a database of clinical information sponsored and administered by Genzyme, have yielded insights that have shaped how doctors and patients manage Gaucher disease. For example, it has been observed in Registry data that Cerezyme therapy decreased the frequency of bone pain and bone crises (severe bone pain), and improved bone mineral density in patients with documented skeletal disease.

Genzyme developed Cerezyme in 1994 in cooperation with the National Institutes of Health. Today, Genzyme is a global leader in research and product development for Gaucher disease and other lysosomal storage disorders.

Indication & Usage

Cerezyme® (imiglucerase for injection) is indicated for long-term enzyme replacement therapy for pediatric and adult patients with a confirmed diagnosis of Type 1 Gaucher disease that results in one or more of the following conditions:

  1. anemia (low red blood cell count)
  2. thrombocytopenia (low blood platelet count)
  3. bone disease
  4. hepatomegaly or splenomegaly (enlarged liver or spleen)

Important Safety Information

Approximately 15% of patients have developed immune responses (antibodies) to Cerezyme during the first year of therapy. These patients have a higher risk of an allergic reaction (hypersensitivity). Your doctor may periodically test for the presence of antibodies. Serious allergic reactions (anaphylaxis) have been reported in less than 1% of patients. Symptoms suggestive of allergic reaction happened in approximately 7% of patients, and include itching, flushing, hives, swelling, chest discomfort, shortness of breath, coughing, cyanosis (a bluish discoloration of the skin due to diminished oxygen), and low blood pressure. If you have had an allergic reaction to Cerezyme, you and your doctor should use caution if you continue to receive treatment with Cerezyme.

High blood pressure in the arteries of the lungs (pulmonary hypertension) and pneumonia have been observed in less than 1% of patients during treatment with Cerezyme. These are also known complications of Gaucher disease regardless of treatment. If you experience symptoms such as shortness of breath or chest pain, with or without fever, contact your doctor.

Approximately 14% of patients have experienced side effects related to treatment with Cerezyme. Some of these reactions occur at the site of injection such as discomfort, itching, burning, swelling or uninfected abscess. Other side effects, each of which was reported by less than 2% of patients, include nausea, abdominal pain, vomiting, diarrhea, rash, fatigue, headache, fever, dizziness, chills, backache, and rapid heart rate. Temporary swelling in the legs has also been observed with drugs like Cerezyme.

Please see Full Prescribing Information (PDF).

Within 4 years of initiating Cerezyme therapy, 93% of patients in the Gaucher Registry met at least 4 of 6 treatment goals.*
* Weinreb N et al. A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase. Am J Hematol. 2008;83(12):890–895.